Benzinga ImmunityBio Clocks 700% Revenue Surge In 2025 From Lead Bladder Cancer Drug
ImmunityBio shares rise after reporting a 700% jump in 2025 revenue, driven by strong Anktiva sales growth and rising demand for its bladder cancer treatment. read more
ImmunityBio shares rise after reporting a 700% jump in 2025 revenue, driven by strong Anktiva sales growth and rising demand for its bladder cancer treatment. read more